| 过雪丹1 吴福林1 陈暑波1 徐伟1 黄庆2.吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌[J].,2012,12(9):1696-1698 |
| 吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌 |
| A Clinical Study on Gemcitabin Combined With cisplatin sequential toGefitinib in the Treatment of Advanced Non- small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 吉西他滨 顺铂 吉非替尼 序贯 非小细胞肺癌 |
| 英文关键词: Gemcitabin Cisplatin Gefitinib Sequential administration Non-small cell lung cancer |
| 基金项目: |
|
| 摘要点击次数: 668 |
| 全文下载次数: 799 |
| 中文摘要: |
| 目的：观察吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌的疗效与毒副反应。方法：71 例经病理学诊断的晚期（Ⅲ
b-Ⅳ期）非小细胞肺癌患者，随机分成两组，观察组给予吉西他滨加顺铂化疗，序贯吉非替尼。对照组给予吉西他滨加顺铂化疗。结
果：两组有效率（RR）为36.1%VS14.3%（P=0.0362）；疾病控制率（DCR）比较x2=14.782，P<0.001;中位生存期(MST)为12.1 月
VS10.8 月（P<0.05）；有统计学差异；观察组除了皮疹、腹泻毒副反应较大外，其他与对照组相仿。结论：吉西他滨联合顺铂序贯吉
非替尼治疗晚期非小细胞肺癌有较好的疗效和安全性，可以扩大样本继续观察。 |
| 英文摘要: |
| Objective: To study with the clinical efficacy and toxicity for adcanced no-small cell lung cancer using Gemcitabin
Combined With cisplatin sequential to Gefitinib rigemen. Methods: 54 cases with pathological dignosis of advanced no-small cell lung
cancer (Ⅲb-Ⅳ) were divided stochastically into gemcitabin combined with cisplatin followed by gefitinib treatment group and gemcitabin
combined with cisplatin group. Results: In 71 cases,the overall response rates (RR) of two groups were 36.1%VS14.3%（P=0.
0362）; The DCR of two groups were 83.3%VS42.9%（x2=14.782，P<0.001）; The median survial time (MST) was 12.1months and
10.8months respectively(P<0.05); There's no statistics difference between two groups but rash and diarrhea. Conclusion: Good clinical efficacy
and safety were achieved in the therapy of adcanced no-small cell lung cancer using Gemcitabin Combined With cisplatin sequential
to Gefitinib rigemen.It is worthy of further enlarged sample research. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
